CD8+ T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas
J. R. Kane, J. Zhao, T. Tsujiuchi, B. Laffleur, A. Mahajan, G. Rao, A. Mela, C. Dmello, V. A. Arrieta, L. Chen, D. Y. Zhang, E. Gonzalez-Buendia, C. Lee-Chang, T. Xiao, G. Rothschild, U. Basu, C. Horbinski, M. S. Lesniak, A. B. Heimberger, R. Rabadan, P. D. Canoll, A. M. Sonabend
Abstract
Cancer immunoediting shapes tumor progression by the selection of tumor cell variants that can evade immune recognition. Given the immune evasion and intra-tumor heterogeneity intrinsic to gliomas, we hypothesized that CD8+ T-cells mediate immunoediting in these tumors. We evaluated glioma progression in the absence of CD8+ T-cells by depleting this immune cell population in transgenic murine gliomas. Upon transplantation, gliomas that developed in the absence of CD8+ T-cells engrafted poorly in recipients with intact immunity but engrafted well in those with CD8+ T-cell depletion. Gliomas developed in absence of CD8+ T-cells exhibited increased chromosomal instability, MAPK signaling, gene fusions, and macrophage/microglial infiltration. MAPK activation correlated with macrophage/microglial recruitment in this model and in the human disease. Our results indicate that CD8+ T-cells mediate immunoediting during gliomagenesis, influencing the genomic stability of glioma and its microenvironment, leading to immune evasion.\n\nSignificanceImmune evasion renders cancer resistant to anti-tumoral immunity. Therapeutic intervention often fails for gliomas because of the plasticity of tumor cell variants that resist immune surveillance. Our results demonstrate a mechanism of immune evasion in gliomas that derives from CD8+ T-cells during the development and progression of this disease.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inflammatory endothelial cells promote infiltration of antigen-licensed cytotoxic T cells in malignant gliomas after irradiation
Clara Tejido, Niklas Graßl, … Katharina Sahm·bioRxiv·Jul 13, 2026
- CD200 depletion in glioma enhances antitumor immunity and induces tumor rejection
Itay Raphael, Anzar Mujeeb, … Michael R. Olin·bioRxiv·Sep 8, 2024
- Agonistic CD40 antibody therapy induces tertiary lymphoid structures but impairs the response to immune checkpoint blockade in glioma
L. van Hooren, A. Vaccaro, … A. Dimberg·bioRxiv·Jan 5, 2021
- CD155 regulates tumor growth and immune evasion in diffuse midline glioma.
Theophilos Tzaridis, Ester Calvo Fernández, … Robert J. Wechsler‐Reya·bioRxiv·Sep 9, 2025
- MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, enhances tumor-microglia crosstalk, and drives immune checkpoint blockade efficacy.
Kwang‐Soo Kim, Junyi Zhang, … Adam M. Sonabend·Nature CommunicationsPeer-reviewed·Jun 25, 2026
- Genetically modified IL-2 bone marrow-derived myeloid cells reprogram the glioma immunosuppressive tumormicroenvironment
A. Canella, M. Nazzaro, … P. Rajappa·bioRxiv·Oct 19, 2022